Srinivasan Vijayakumar, Samir Narayan, Claus Chunli Yang, Philip Boerner, Rojymon Jacob, Mathew Mathai, Rick Harse, James Purdy
{"title":"Introducing new technologies into the clinic.","authors":"Srinivasan Vijayakumar, Samir Narayan, Claus Chunli Yang, Philip Boerner, Rojymon Jacob, Mathew Mathai, Rick Harse, James Purdy","doi":"10.1159/000106035","DOIUrl":null,"url":null,"abstract":"<p><p>Introducing new technologies into radiation oncology clinical practices poses very specific logistical dilemmas. How do we determine that a new technology's dose distribution is better than the 'standard' and what are the methods that can be applied to easily compare the 'new' with the 'old'? We consider how the benchmark dose-volume histogram (DVH) can serve as a conceptual model to approach these issues. Comparing dosimetric differences using benchmark DVHs helps a 'global' comparison of the area under the curve that is intuitive, relatively efficient and easily implemented. These concepts, applied in prostate cancer in this communication, have wider applications in other disease sites and in the introduction of technologies beyond intensity-modulated radiation therapy.</p>","PeriodicalId":55140,"journal":{"name":"Frontiers of Radiation Therapy and Oncology","volume":"40 ","pages":"180-192"},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000106035","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Radiation Therapy and Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000106035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5
Abstract
Introducing new technologies into radiation oncology clinical practices poses very specific logistical dilemmas. How do we determine that a new technology's dose distribution is better than the 'standard' and what are the methods that can be applied to easily compare the 'new' with the 'old'? We consider how the benchmark dose-volume histogram (DVH) can serve as a conceptual model to approach these issues. Comparing dosimetric differences using benchmark DVHs helps a 'global' comparison of the area under the curve that is intuitive, relatively efficient and easily implemented. These concepts, applied in prostate cancer in this communication, have wider applications in other disease sites and in the introduction of technologies beyond intensity-modulated radiation therapy.